Skip to main content
Northwestern University Feinberg School of Medicine
Department of Dermatology
Skip to main content

Clinical Trials

Clinical and outcomes research under the direction of the Department of Dermatology is conducted both at the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago dermatology clinics. For more information about the research or participation, please call our office at 312-695-6829.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about our work via the Feinberg Office of Research Clinical Trials page.

Trials
DERMATOLOGY TISSUE ACQUISITION AND REPOSITORY
Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood, saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body passages and cavities such as the inside of your mouth or nose), and ot…
Northwestern University’s Department of Dermatology is collecting skin, hair, nail, blood, saliva, skin and/or buccal swabs, and mucous membrane(part of your skin which lines body passages and cavities such as the inside of your mouth or nose), and other tissue samples for use in a biorepository. By operating this biorepository, the Department of Dermatology hopes to develop a better understanding of skin diseases (meaning the knowledge about how cells in the skin behave and react to medical treatments) among researchers at Northwestern University and other approved researchers. This basic knowledge is expected to help the development of more effective patient care and new treatment methods.
-Having specimens collected as part of a standard of care procedure;
-Have a skin disease which researchers want samples of in order to further understand
it; or
-Qualify as a healthy volunteer whose samples researchers can use as control samples
for research.
Rangel, Stephanie MarieRangel, Stephanie Marie
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00009443
More Info

For more information on this study please contact us:

Belback, Madeleine 312 503 5901
Copy
A Phase 3 Multicenter, Randomized, Placebo-Controlled Study to Determine the Efficacy of Topical SGX301 and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma
To evaluate the safety and effectiveness of the topical ointment (cream), SGX301, in combination with light the…
To evaluate the safety and effectiveness of the topical ointment (cream), SGX301, in combination with light therapy in patients with cutaneous T-cell lymphoma.
Must be 18 years of age or older, with a clinical diagnosis of Cutaneous T- Cell Lymphoma, Myucosis Fungoides, Stage IA. Stage IB, or Stage IIA, and willing to refrain from sunbathing for duration of the study.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02448381 STU00200530
More Info

For more information on this study please contact us:

Bagnowski, Katherine +1 312 503 3788
Copy
AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
The purpose of this study is to validate a specific itch tool and its relation to skin disease severity in children ages 5-17 who have symptoms of itch (ie, primary dermatologic conditions: atopic dermatitis, epidermoly…
The purpose of this study is to validate a specific itch tool and its relation to skin disease severity in children ages 5-17 who have symptoms of itch (ie, primary dermatologic conditions: atopic dermatitis, epidermolysis bullosa, ichthyosis, psoriasis, etc; or other conditions that result in itch such as cancer and pruritic responses to therapy, chronic liver or renal diseases, patients who receive cancer therapy) The study will look at how well Patient Reported Outcomes Measurement Information System (PROMIS) tools uncover meaningful changes in disease status as well as build a list of items relating to pediatric skin diseases and a PRO model for signs and symptoms of skin disease. Surveys can be done remotely.
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00202292
More Info

For more information on this study please contact us:

Ramachandran, Divya 312 503 5914
Copy
Defining the Skin and Blood Biomarkers of Ichthyosis
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper…
Ichthyosis is a group of genetic skin disorders that present with dry, thickened, scaly, or flaky skin. As of today, there is no cure or treatment. Doctors can only treat the dry skin with different types of emollients to soften the scale. A deeper understanding of this disease is required to develop better treatments. There are different types of cells and cell-produced signals (biomarkers) that are being studied in order to help find these new treatments. Looking at biomarkers has been successful in helping us to understand other skin disorders better. The purpose of this study is to determine which blood and skin biomarkers characterize ichthyosis in children.
Subjects (1 year to 60 years of age) with Autosomal Recessive Congenital Ichthyosis (ARCI), which includes lamellar Ichthyosis, Netherton Syndrome, or other ichthyosis subtypes will be enrolled.
Healthy control subjects will be enrolled for either a blood sample or skin sample, and/or tape strip samples.
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 1131 Techny Rd.
    Northbrook, IL
STU00203051
More Info

For more information on this study please contact us:

Canter, Talia 312 503 5917
Copy
Defining The Skin and Blood Biomarkers of Pediatric Atopic Dermatitis
Atopic dermatitis (AD), also called eczema, is a disease in which the skin is dry and scaly with severe itching that may continue despite treatment. A deeper understanding of this disease is required to develop new and better treat…
Atopic dermatitis (AD), also called eczema, is a disease in which the skin is dry and scaly with severe itching that may continue despite treatment. A deeper understanding of this disease is required to develop new and better treatments. There are different types of cells and cell-produced signals (biomarkers) that have been found in adults with AD. Nevertheless, there may be significant differences between AD in children versus adults. The purpose of this study is to determine which blood and skin biomarkers characterize AD in children by looking at the blood and skin biomarkers of children with AD and children without AD.
This study will enroll children ages 0 months to 17 years to collect blood, skin, saliva and tape strip samples in order to look at biomarkers related to AD. Children who have or have not been diagnosed with AD or an atopic condition, such as allergies or asthma.
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
  • Map it 225 E. Chicago Ave.
    Chicago, IL
  • Map it 1131 Techny Rd.
    Northbrook, IL
STU00203272
More Info

For more information on this study please contact us:

Canter, Talia 312 503 5917
Copy
A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms of Cutaneous T-Cell Lymphoma (CTCL)
The main goal of …
The main goal of this study is to test the efficacy and safety of topical Naloxone for itching in patients with MF.
21 years of age or older with a diagnosis of mycosis fungoides (MF) with itching present on a daily basis for more than one month and willing to fill out a diary for 7 days to provide severity of itch before enrollment.
Guitart, JoanGuitart, Joan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02811783 STU00203078
More Info

For more information on this study please contact us:

Bagnowski, Katherine +1 312 503 3788
Copy
A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for Epidermal Growth Factor Receptor Inhibitor-Induced Papulopustular Eruption
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. T…
EGFR inhibitors are biologic agents used to treat certain cancers including non-small cell lung, colorectal, head and neck, and pancreatic carcinomas. These agents often have a side effect of an acne like rash that in some cases can be quite severe. This rash has been shown to be inflammatory in origin but is currently treated with antibiotics if it appears. The main goal of this study is to test if patients treated with steroid cream, (added) which is an anti-inflammatory medication, (added) before a rash develops have a less severe rash than patients who do not use a steroid cream before a rash develops.
Must be 18 years of age or older with a diagnosis of cancer and starting an (changed from 'and') EGFR inhibitor. During the study you must be willing to fill out a daily diary, use sunscreen and cream daily, and fill out 2 questionnaires and have photographs taken every 2 weeks for 4 visits.
Choi, JenniferChoi, Jennifer
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03115567 STU00203631
More Info

For more information on this study please contact us:

Erickson, Maia 312 503 4347
Copy
Corrona Psoriasis Registry
The main purpose of the Corrona Psoriasis registry is to learn more about psoriasis, how doctors treat psoriasis, how well medications and treatments work, and the safety of those treatments.
To be eligible, you need to be 18 years of age or older, have been diagnosed with psoriasis by a dermatologist, and have started on or switched to a systemic biologic psoriasis treatment within the previous 12 months by a Northwestern dermatologist.
Amin, AhmadAmin, Ahmad
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00203552
More Info
psoriasis

For more information on this study please contact us:

Paiva Costa TeixeiraFigueiredo, Anna Carolina 312 503 5909
Copy
Gene Expression and Biomarker Profiling of Keloid Skin Sub-Study: A Pilot Trial of Keloid Genomic Profiling Using RNAseq
Northwestern’s Department of Dermatology is performing a research study to better understand the causes of keloid scars. Keloid scars are solid tissue overgrowths that tend to d…
Northwestern’s Department of Dermatology is performing a research study to better understand the causes of keloid scars. Keloid scars are solid tissue overgrowths that tend to develop after trauma to the skin.
Subjects who are 18 years of age or older. Have no history of keloids or have a keloid on the earlobe or on another area of your body that either has not been treated or if treated, the treatment took place more than 6 months ago.
Kundu, Roopal VashiKundu, Roopal Vashi
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03228693 STU00203462
More Info
keloid

For more information on this study please contact us:

Ali, Yasmeen 312 503 5906
Copy
The Gut and Skin Microbiome in Vitiligo Disease Progression

Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and …

Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time swab or tape strip samples of the skin and swab samples of stool will be collected. All subjects will be asked to complete questionnaires about their skin care regimen and dietary habits. Subjects with vitiligo will be required to follow up for additional specimen collection and questionnaire completion after six months and one year.

Volunteers over the age of 18 are eligible to participate. Study is recruiting those with and without vitiligo. 
Le Poole, IsabelleLe Poole, Isabelle
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00206844
More Info

For more information on this study please contact us:

Belback, Madeleine 312 503 5901
Copy
The Impact of Pediatric Skin Disorders: The “Big” Study

The purpose of this study is to understand the possible burden of skin disorders in school-age children, such as its impact on the development of anxiety, depression and relationships with friends. The study will look at the relationship …

The purpose of this study is to understand the possible burden of skin disorders in school-age children, such as its impact on the development of anxiety, depression and relationships with friends. The study will look at the relationship between the burden and how severe or visible the skin problem is.​ Surveys can be done remotely.

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00207281
More Info

For more information on this study please contact us:

Canter, Talia 312 503 5917
Copy
(xIRB) Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

Psoriasis is a skin condition that causes red, scaly, itchy patches on the skin. Psoriasis is associated with inflammation that may play a role in heart disease, stroke, diabetes, obes…

Psoriasis is a skin condition that causes red, scaly, itchy patches on the skin. Psoriasis is associated with inflammation that may play a role in heart disease, stroke, diabetes, obesity and other metabolic disease. Lipoproteins (substances made up of fat and protein), cholesterol, and other proteins associated with inflammation have specifically been shown to be abnormal in psoriasis patients. The purpose of this study is to investigate if systemic psoriasis medication changes the makeup of these inflammatory substances and lipoproteins in the blood. If systemic therapy is shown to improve levels of these substances in the blood,it may indicate prevention against the development of heart disease, stroke,diabetes, obesity and other metabolic disease. Subjects will be required to have one fasting blood draw for collection of research samples. 

Ages 6 to 17 years and havepsoriasis, acne, or are healthy volunteers. Participants with psoriasis musthave a 6 month or more history of treatment with a topical medication or have a3 month or less history of treatment with a systemic (works throughout thewhole body) medication. Participants with acne must currently be treated with amedication called isotretinoin. Participants who are healthy volunteers areasked to participate because they have the same body composition as anotherparticipant in this study with psoriasis or acne. 

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208518
More Info

For more information on this study please contact us:

Fang, Milie
Copy
Genetic Analysis of Pediatric Psoriasis

Psoriasis is a skin condition that causes red, scaly, itchy patches. There is a gene called CARD14 and some mutations in CARD14 cause psoriasis in both children and adults. These mutations can be passed down from parents to children in families, but a child …

Psoriasis is a skin condition that causes red, scaly, itchy patches. There is a gene called CARD14 and some mutations in CARD14 cause psoriasis in both children and adults. These mutations can be passed down from parents to children in families, but a child with no family history of psoriasis could also have a new mutation in CARD14 that causes psoriasis.

The purpose of this study is to see what kinds of mutations in the CARD14 gene cause psoriasis and what new mutations in other genes can cause psoriasis in a child with no family history of psoriasis. Participants will be assessed for demographics, clinical, medication, and family history as well as severity of psoriasis at the study visit (in-clinic or over the phone). Saliva samples or buccal swabs will be obtained from all subjects.

Patients of any age who developedpsoriasis before 12 years of age and who have no family history of psoriasis ineither parent, parents of patients who developed psoriasis before 12 years ofage, and up to third-degree family members (first cousin, grandparent,great-grandparent) with or without psoriasis if family history is indicated.All participants must be able to give a saliva or buccal swab sample. 

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208556
More Info

For more information on this study please contact us:

Singh, Prableen +1 312 227 6485
Copy
Wool Clothing for Atopic Dermatitis
This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to stan…
This is a clinical research study that aims to determine if there is an improvement in eczema in children when they wear superfine merino wool clothing. Participants will be randomly assigned to two groups and begin with wool garments for 6 weeks and switch to standard garments for 6 weeks or begin with standard garments for 6 weeks and switch to wool garments for a further 6 weeks. Participants will attend follow-up appointments at 3, 6, 9 and 12 weeks where severity of eczema,quality of life, and any side effects will be assessed. Wool clothing and laundry detergent will be provided for the duration of the entire study. 

Ages 3 months to 5 years with moderate to severe eczema as determined atinitial visit.

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00208730
More Info

For more information on this study please contact us:

Ramachandran, Divya +1 312 503 5944
Copy
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
MeasureUp 1 is a clinical research study that will test if the study drug “upadacitinib”is better than placebo at treating moderate to s…
MeasureUp 1 is a clinical research study that will test if the study drug “upadacitinib”is better than placebo at treating moderate to severe atopic dermatitis. Inthis study, you will either get the study drug (upadacitinib) or a placebo. Theeffectiveness and safety of upadacitinib will be judged by a range ofassessments that rate the severity and extent of atopic dermatitis, itch andseveral other symptoms, as well as general health status and quality of life.
Ages12 to 75 with symptoms of moderate to severe atopic dermatitis for at least 3years, and have had inadequate response to treatment with topical medication orhave been taking systemic treatments in the last 6 months. 
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03569293 STU00207913
More Info

For more information on this study please contact us:

Onate, Alejandra 312 503 5908
Copy
(xIRB) Prospective, observational, longitudinal study in pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable

PEDISTAD is an observational study to assess the …

PEDISTAD is an observational study to assess the features of children with moderate to severe atopic dermatitis, also called eczema,whose disease is not adequately controlled with topical therapies (creams orlotions) or when those therapies are not medically advisable.

Participants in this non-interventional study will be treated in the usual way for their conditions and will not undergo extra tests. The study will document how atopic dermatitis and other diseases linked to atopic dermatitis changes over time and will also investigate the influence of routine clinical practice on clinical results to understand how atopic dermatitis affects children and their caregivers in their daily lives. There is an optional, additional study that will also enroll subjects for the collection of research specimens during regularly scheduled clinic appointments for biomarker analysis. 

Ages <12 years old with moderate to severe atopic dermatitiswho are currently receiving systemic treatment (including phototherapy) foratopic dermatitis, or currently on topical treatment but otherwise candidatesfor systemic treatment for either lack of adequate control and/or safetyconcerns with long-term topical treatment. 

Kruse, LaceyKruse, Lacey
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00209263
More Info

For more information on this study please contact us:

Singh, Prableen +1 312 227 6485
Copy
XIRB-A pragmatic trial of home versus office based narrow band ultraviolet B phototherapy for the treatment of psoriasis

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB photo…

The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband UVB phototherapy for the treatment of psoriasis. Phototherapy delivered at home or the office are both common treatments for psoriasis but it is not known how well they compare to one another.

12 years or older with plaque or guttate psoriasis predominantly on trunk and/or extremities. Patient needs to be willing to comply with in-office or in-home phototherapy.  
Amin, AhmadAmin, Ahmad
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00209270
More Info

For more information on this study please contact us:

Paiva Costa TeixeiraFigueiredo, Anna Carolina 312 503 5909
Copy
An Open Label, Pilot Study Evaluating the Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy re…

This study will test if low-dose oral minoxidil has aneffect on permanent chemotherapy-induced alopecia (defined as hair loss afterthe completion of a chemotherapy regimen that persists for over six months). Inthis study, you will receive the study drug; there is no placebo option. Theeffectiveness and safety of the treatment will be determined by a range of assessments,including biopsies, images, and subjective evaluation of perceived hair growth.

Age 18 and above with a diagnosis of permanentchemotherapy-induced alopecia and agree to use contraception for the durationof the study.

Choi, JenniferChoi, Jennifer
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03831334 STU00206882
More Info

For more information on this study please contact us:

Erickson, Maia 312 503 4347
Copy
Moderate to Severe Atopic Dermatitis: Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects
ADUp is a clinical research study that will test if the study drug “upadacitinib”in combination with topical corticosteroids (TCS) is better than placebo i…
ADUp is a clinical research study that will test if the study drug “upadacitinib”in combination with topical corticosteroids (TCS) is better than placebo incombination with TCS at treating moderate to severe atopic dermatitis. In thisstudy, you will either get the study drug (upadacitinib) with TCS or a placebowith TCS. The effectiveness and safety of upadacitinib will be judged by arange of assessments that rate the severity and extent of atopic dermatitis,itch and several other symptoms, as well as general health status and qualityof life.
Ages12 to 75 with a diagnosis of moderate to severe atopic dermatitis for at least 3years, and have had inadequate responses or intolerance to treatment withtopical medication within 6 months prior to the baseline visit. 
Paller, AmyPaller, Amy
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03568318 STU00207896
More Info

For more information on this study please contact us:

Onate, Alejandra 312 503 5908
Copy
A Randomized, Single-Blind, Placebo-controlled, Self-matched pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of 0.03% RGN-137 Topical Gel in Subjects with Junctional and Dystrophic Epidermolysis Bullosa

Epidermolysis bullosa(EB) is a group of genetic conditions that cause …

Epidermolysis bullosa(EB) is a group of genetic conditions that cause blistering of the skin. In the Junctional EB (JEB) and Dystrophic EB (DEB) subtypes, EB wounds do not heal easily and can result in permanent and disfiguring scarring. The experimental drug in this study, a Tβ4 topical gel, is being tested in these two subtypes because of Tβ4’s wound healing characteristics. The study will compare how well 0.03% RGN-137 (Tβ4 topical gel)works and how safe it is compared to a placebo gel (which looks like the study drug but does not have any active drug ingredient) in the treatment of JEB or DEB.

Males or females who are at least 4 years old with adiagnosis of Junctional EB (JEB) or Dystrophic EB (DEB).

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT03578029 STU00209415
More Info

For more information on this study please contact us:

Parker, Jennifer
Copy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata

Alopecia Areata is much more than losing your hair. It’s an autoimmun…

Alopecia Areata is much more than losing your hair. It’s an autoimmune condition that can cause severe emotional distress, including depression and anxiety  - and can get in the way of living a full life. There are no FDA approved treatments for Alopecia Areata, but researchers are working hard to change that. A clinical research study is now underway throughout the country– and is seeking volunteers with Alopecia Areata affecting at least half of their scalp to participate. Qualified participants will receive study-related care and investigational medication at no cost to them. 

You mayqualify if you:

  • Are at least 18 years of age
  • Have experienced at least 50% of hair loss due to Alopecia Areata
Colavincenzo, Maria LColavincenzo, Maria L
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03570749 STU00208323
More Info

For more information on this study please contact us:

Paiva Costa TeixeiraFigueiredo, Anna Carolina 312 503 5909
Copy
Phase 2b dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g compared to delgocitinib cream vehicle over an 8-week treatment period in adult subjects with atopic dermatitis

LP0133-1275 is a clinical research study that will testdifferent strengths of the investigational study dr…

LP0133-1275 is a clinical research study that will testdifferent strengths of the investigational study drug “delgocitinib” for the treatmentof mild to severe atopic dermatitis. In this study, you will get assigned toapply (twice daily for 8 weeks) 1 mg, 3 mg, 8 mg, 20 mg of delgocitinib cream,or you will be assigned to apply a delgocitinib cream vehicle (placebo). Theeffectiveness and safety of delgocitinib will be judged by a range ofassessments that rate the severity and extent of atopic dermatitis, itch andseveral other symptoms, as well as general health status and quality of life.

Age 18 and older with a diagnosis of mild to severe atopicdermatitis for at least 1 year, and have 5-50% body surface involvement (excludingscalp) of atopic dermatitis.

Liszewski, WalterLiszewski, Walter
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03725722 STU00208929
More Info

For more information on this study please contact us:

Onate, Alejandra 312 503 5908
Copy
A Phase 2 Study of pembrolizumab in patients with histiocyte/dendritic cell neoplasms and biologically selected subtypes of relapsed/refractory aggressive lymphomas. (Protocol #17-448)

This is a clinical research study to test the safety and effectiveness of the study drug, pembrolizumab, in treat…

This is a clinical research study to test the safety and effectiveness of the study drug, pembrolizumab, in treating patients with an aggressive lymphoma or a histiocyte or dendritic cell neoplasm (tumor) that hasnot responded to or has come back after other treatments. The effectiveness and safety of the treatment will be determined by a range of assessments including biopsies, scans (or imaging tests), as well as general health and performance status. 

Age 18 and above with a diagnosis of a histiocyte/dendritic cell neoplasm or relapsed/refractory aggressive lymphoma. Must be willing to provide tissue from a newly obtained biopsy, have normal organ and marrow function and not a candidate for potentially curative therapy at the time of enrollment.

Choi, JaehyukChoi, Jaehyuk
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03316573 STU00209675
More Info
lymphoma

For more information on this study please contact us:

Bagnowski, Katherine +1 312 503 3788
Copy
A Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-06651600 in Adult and Adolescent Alopecia Areata (AA) Subjects with 50% or Greater Scalp Hair Loss
The purpose of this study is to compare the effects of the study drug with a pl…
The purpose of this study is to compare the effects of the study drug with a placebo to find out which is better for treating alopecia areata. Subjects will be asked to visit the study site about 14 times during the study.

Subjects who are 12 years and older with alopecia areata and >50% hair loss of the scalp. The current episode of hair loss needs to be less than 10 years. 

Colavincenzo, Maria LColavincenzo, Maria L
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03732807 STU00209009
More Info

For more information on this study please contact us:

Paiva Costa TeixeiraFigueiredo, Anna Carolina 312 503 5909
Copy
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis
HeadsUp is a clinical research study that compares the effectiveness and safety ofupadacit…
HeadsUp is a clinical research study that compares the effectiveness and safety ofupadacitinib versus dupilumab for the treatment of adult subjects  with moderate to severe atopic dermatitis(AD) who are candidates for systemic therapy (treatment with medication thattravels through the bloodstream). The effectiveness and safety of upadacitinib anddupilumab will be judged by a range of assessments that rate the severity andextent of atopic dermatitis, itch and several other symptoms, as well asgeneral health status and quality of life.

Ages 18 to 75 with a diagnosis of moderate to severe atopicdermatitis for at least 3 years, and have had inadequate response orintolerance to treatment with topical corticosteroids (steroidal treatment thatis applied directly to your skin, i.e. triamcinolone acetonide), topicalcalcineurin inhibitors (non-steroidal treatment that is applied to your skinthat regulates your immune system, i.e. tracolimus and pimecrolimus), orsystemic treatment in the last 6 months .(treatment with medication that travelsthrough the bloodstream) 

Silverberg, JonathanSilverberg, Jonathan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT03738397 STU00209541
More Info

For more information on this study please contact us:

Onate, Alejandra
Copy
Back to top